David Morris, MD, FACS; John Phillips, MD; Jeremy McDuffie, MD; Katy Beckermann, MD, PhD; and Alan Tan, MD, explore the distinct roles of alpha and beta emitters in radiopharmaceutical therapy, the promise of triplet therapy, and the integration of precision medicine in the final segment of this roundtable series. They discuss the operational challenges and clinical considerations of radioligand therapies like lutetium-177 PSMA and radium, their impact on patient outcomes, and the potential to move these therapies earlier in the treatment paradigm. ...
mHSPC/mCSPC
Advertisement
Dr. Greenstein shares insights on the overall survival benefit of apalutamide over enzalutamide in a recent real-world study.
Dr. Armstrong reviews a handful of GU studies presented, including NIAGRA and STAMPEDE.
Drs. Tawagi and Wallis review the PEACE-III, STAMPEDE, UpFrontPSMA, and SPLASH studies trials at the ESMO Congress 2024.
The panel concludes with thoughts on the evolving landscape of PC treatment, focusing on multidisciplinary collaboration.
Future Directions in Metastatic PC: Exploring Monotherapy, Novel Therapies, and Strategic Sequencing
The panel ponders the future of metastatic prostate cancer treatment, emphasizing the potential of emerging therapies.
The panel considers the decision-making process for chemo eligibility in mHSPC, emphasizing the role of patient education.
Implementing Triplet Therapy for mHSPC: Collaboration, Patient Communication, and QOL Considerations
The panel delves into triplet therapy for mHSPC, highlighting the benefits and logistics of the ARASENS regimen.
The panel shares insights on managing mHSPC, emphasizing patient communication and evolving role of novel therapies.
Advertisement
Prostate Cancer Knowledge Hubs
Conference Coverage
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
In the PENELOPE study, TAR-200 showed greater tissue penetration of gemcitabine compared to standard intravesical therapy.
The panelists share their insights on risk assessment, and customized treatment strategies for high-risk NMIBC.
The panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies.
The panelists debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors.
Advertisement
Advertisement
Latest News
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Dr. Daneshmand discusses the impressive complete response rate and durability of TAR-200 monotherapy for NMIBC.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.